Literature DB >> 26690534

Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

Rania Abdelhedi1, Nouha Abdelmoula Bouayed, Suad Alfadhli, Leila Abid, Ahmed Rebai, Najla Kharrat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26690534     DOI： 10.1007/s12041-015-0581-2

Source DB:  PubMed          Journal:  J Genet        ISSN： 0022-1333            Impact factor:   1.166


× No keyword cloud information.
  19 in total

1.  Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.

Authors:  Maria Gabriella Scordo; Achille P Caputi; Concetta D'Arrigo; Giuseppina Fava; Edoardo Spina
Journal:  Pharmacol Res       Date:  2004-08       Impact factor: 7.658

2.  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Authors:  Al-Motassem Yousef; Nailya R Bulatova; William Newman; Nancy Hakooz; Said Ismail; Hisham Qusa; Farah Zahran; Nidaa Anwar Ababneh; Farah Hasan; Imad Zaloom; Ghada Khayat; Rawan Al-Zmili; Randa Naffa; Ola Al-Diab
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

3.  Genotyping: one piece of the puzzle to personalize antiplatelet therapy.

Authors:  Paul A Gurbel; Udaya S Tantry; Alan R Shuldiner; Dean J Kereiakes
Journal:  J Am Coll Cardiol       Date:  2010-05-13       Impact factor: 24.094

4.  Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles.

Authors:  K-A Kim; W-K Song; K-R Kim; J-Y Park
Journal:  J Clin Pharm Ther       Date:  2010-12       Impact factor: 2.512

5.  Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent.

Authors:  Guilherme Suarez-Kurtz
Journal:  Eur J Clin Pharmacol       Date:  2010-10-03       Impact factor: 2.953

6.  Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.

Authors:  Jorge Vicente; Fabricio González-Andrade; Antonia Soriano; Ana Fanlo; Begoña Martínez-Jarreta; Blanca Sinués
Journal:  Mol Biol Rep       Date:  2014-01-16       Impact factor: 2.316

7.  Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.

Authors:  Samar Ismail Hamdy; Masahiro Hiratsuka; Kaori Narahara; Mervat El-Enany; Nadia Moursi; Mohammed Salah-Eldin Ahmed; Michinao Mizugaki
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

8.  Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Authors:  Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati
Journal:  Circulation       Date:  2010-01-18       Impact factor: 29.690

9.  Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations.

Authors:  Jue Quin Yang; Sandrine Morin; Céline Verstuyft; Li An Fan; Yong Zhang; Chun Di Xu; Véronique Barbu; C Funck-Brentano; Patrice Jaillon; Laurent Becquemont
Journal:  Fundam Clin Pharmacol       Date:  2003-06       Impact factor: 2.748

10.  Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.

Authors:  J A Goldstein; T Ishizaki; K Chiba; S M de Morais; D Bell; P M Krahn; D A Evans
Journal:  Pharmacogenetics       Date:  1997-02
View more
  4 in total

1.  Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?

Authors:  Saoussen Chouchene; Rym Dabboubi; Haythem Raddaoui; Hela Abroug; Khaldoun Ben Hamda; Sondess Hadj Fredj; Fatma Abderrazak; Mayssa Gaaloul; Marwa Rezek; Fadoua Neffeti; Ilhem Hellara; Mouna Sassi; Linda Khefacha; Asma Sriha; Semir Nouira; Mohamed Fadhel Najjar; Faouzi Maatouk; Taieb Messaoud; Mohsen Hassine
Journal:  Eur J Clin Pharmacol       Date:  2018-08-03       Impact factor: 2.953

2.  Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.

Authors:  Helmi Ammar; Zohra Chadli; Ahmed Mhalla; Sabria Khouadja; Ibtissem Hannachi; Mohammed Alshaikheid; Ahlem Slama; Nadia Ben Fredj; Najeh Ben Fadhel; Haifa Ben Romdhane; Amel Chaabane; Naceur A Boughattas; Lotfi Gaha; Lazhar Zarrouk; Karim Aouam
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

3.  Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations.

Authors:  Haifa Jmel; Lilia Romdhane; Yosra Ben Halima; Meriem Hechmi; Chokri Naouali; Hamza Dallali; Yosr Hamdi; Jingxuan Shan; Abdelmajid Abid; Henda Jamoussi; Sameh Trabelsi; Lotfi Chouchane; Donata Luiselli; Sonia Abdelhak; Rym Kefi
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

Review 4.  Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.

Authors:  Renée Dagenais; Kyle John Wilby; Hazem Elewa; Mary H H Ensom
Journal:  Drugs R D       Date:  2017-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.